Celltrion Inc
π°π·South Korea
- Country
- π°π·South Korea
- Ownership
- -
- Established
- 1999-01-01
- Employees
- -
- Market Cap
- $31.9B
- Website
- http://www.celltrion.com/
A Study to Compare Pharmacokinetics, Efficacy and Safety of Subcutaneous CT-P44 and Darzalex Faspro in Combination With Lenalidomide and Dexamethasone in Patients With Refractory or Relapsed Multiple Myeloma
Phase 3
Not yet recruiting
- Conditions
- Refractory or Relapsed Multiple Myeloma
- Interventions
- Biological: CT-P44(Daratumumab)Biological: Darzalex Faspro(Daratumumab)
- First Posted Date
- 2025-05-01
- Last Posted Date
- 2025-05-04
- Lead Sponsor
- Celltrion
- Target Recruit Count
- 486
- Registration Number
- NCT06952478
A Study to Compare the Auto-injector and Pre-filled Syringe of CT-P43 in Healthy Male Subjects
- First Posted Date
- 2025-04-30
- Last Posted Date
- 2025-04-30
- Lead Sponsor
- Celltrion
- Target Recruit Count
- 160
- Registration Number
- NCT06951828
- Locations
- π°π·
Korea University Guro Hospital, Seoul, Guro-gu, Korea, Republic of
A Study to Compare Effects and Safety of CT-P51 and Keytruda in Patients With Previously Untreated Metastatic Lung Cancer
Phase 3
Recruiting
- Conditions
- Non Squamous Non Small Cell Lung Cancer
- Interventions
- Drug: EU-approved Keytruda
- First Posted Date
- 2025-04-23
- Last Posted Date
- 2025-04-23
- Lead Sponsor
- Celltrion
- Target Recruit Count
- 606
- Registration Number
- NCT06939595
- Locations
- π¬πͺ
ltd "Institute of Clinical Oncology", Tbilisi, Georgia
A Phase 3 Study to Evaluate Efficacy & Safety of Subcutaneous CT-P13 in Patients With Moderate to Severe Active Rheumatoid Arthritis
Phase 3
Active, not recruiting
- Conditions
- Moderately to Severely Active Rheumatoid Arthritis
- Interventions
- Biological: CT-P13 SC Auto-InjectorBiological: Placebo Auto-Injector
- First Posted Date
- 2024-12-18
- Last Posted Date
- 2025-04-25
- Lead Sponsor
- Celltrion
- Target Recruit Count
- 192
- Registration Number
- NCT06738719
- Locations
- π΅π±
Klinika Reuma Park Sp. z.o.o, Warsawa, Poland
To Compare the Pharmacokinetics, Safety, and Immunogenicity of Subcutaneous CT-P6 and Herceptin in Healthy Male Subjects (Trastuzumab)
Phase 1
Recruiting
- Conditions
- Healthy
- Interventions
- Biological: CT-P6 SC
- First Posted Date
- 2024-11-14
- Last Posted Date
- 2025-05-22
- Lead Sponsor
- Celltrion
- Target Recruit Count
- 200
- Registration Number
- NCT06687928
- Locations
- π°π·
Celltrion, Yeonsu-gu, Incheon, Korea, Republic of
A Study to Compare Efficacy and Safety of CT-P55 and Cosentyx in Patients with Moderate to Severe Psoriasis
Phase 3
Not yet recruiting
- Conditions
- Plaque Psoriasis
- Interventions
- First Posted Date
- 2024-10-08
- Last Posted Date
- 2024-10-08
- Lead Sponsor
- Celltrion
- Target Recruit Count
- 375
- Registration Number
- NCT06630559
Efficacy and Safety of Pioglitazone Combination Therapy in Type 2 Diabetes Patients on a Background of Empagliflozin With Metformin
Phase 3
Recruiting
- Conditions
- T2DM
- Interventions
- First Posted Date
- 2024-08-26
- Last Posted Date
- 2024-08-26
- Lead Sponsor
- Celltrion
- Target Recruit Count
- 582
- Registration Number
- NCT06571591
- Locations
- π°π·
Celltrion, Incheon, Korea, Republic of
Phase I Study to Compare the Pharmacokinetics, Pharmacodynamics, and Safety Between CT-P41 and US-licensed Prolia in Healthy Male Subjects
Phase 1
Completed
- Conditions
- Healthy Subject
- Interventions
- Biological: CT-P41Biological: US-licensed Prolia
- First Posted Date
- 2023-09-14
- Last Posted Date
- 2023-09-14
- Lead Sponsor
- Celltrion
- Target Recruit Count
- 154
- Registration Number
- NCT06037395
- Locations
- π°π·
CHA Bundang Medical Center, Seongnam, Bundang-gu, Korea, Republic of
π°π·Chungnam National University Hospital, Daejeon, Jung-gu, Korea, Republic of
A Bioequivalence Study of L04TD3 Compared to Administration of L04RD1 in Healthy Volunteers
- First Posted Date
- 2023-08-15
- Last Posted Date
- 2023-08-15
- Lead Sponsor
- Celltrion
- Target Recruit Count
- 50
- Registration Number
- NCT05993806
- Locations
- π°π·
H plus Yangji Hospital, Seoul, Korea, Republic of
A Study to Compare Efficacy, Pharmacokinetics, Pharmacodynamics and Safety of CT-P53 and Ocrevus in Patients With Relapsing-remitting Multiple Sclerosis
Phase 3
Recruiting
- Conditions
- Relapsing-remitting Multiple Sclerosis
- Interventions
- Biological: CT-P53Biological: US-OcrevusBiological: EU-Ocrevus
- First Posted Date
- 2023-06-18
- Last Posted Date
- 2024-05-22
- Lead Sponsor
- Celltrion
- Target Recruit Count
- 512
- Registration Number
- NCT05906992
- Locations
- π΅π±
CT-P53 3.1 investigational site, PoznaΕ, Poland